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Abstract:  
 
Objectives: It has been suggested that treatment of STIs with azithromycin may facilitate 
development of azithromycin resistance in Neisseria gonorrhoeae (NG) by exposing the organism to 
sub-optimal doses. We investigated whether treatment history for non-rectal Chlamydia trachomatis 
(CT), non-gonococcal urethritis (NGU) or NG (proxies for azithromycin exposure) in sexual health 
(GUM) services was associated with susceptibility of NG to azithromycin. 
 
Methods: Azithromycin susceptibility data from the Gonococcal Resistance to Antimicrobials 
Surveillance Programme (GRASP 2013-15, n=4606) and additional high-level azithromycin resistant 
isolates (HL-AziR) identified by the Public Health England reference laboratory (2013-2016, n=54) 
were matched to electronic patient records in the national GUMCAD STI surveillance dataset (2012-
2016). Descriptive and regression analyses were conducted to examine associations between history 
of previous CT/NGU/NG and subsequent susceptibility of NG to azithromycin.  
 
Results: Modal azithromycin Minimum Inhibitory Concentration (MIC) was 0.25 mg/L (1 dilution 
below the resistance breakpoint) in those with and without history of previous CT/NGU/NG 
(previous 1 month/6 months).  There were no differences in MIC distribution by history of CT/NGU 
(p=0.98) or NG (p=0.85) in the previous 1month/6 months, nor in the odds of having an elevated 
azithromycin MIC (>0.25 mg/L) (Adjusted Odds Ratio for CT/NGU 0.97 (95% CI 0.76-1.25); AOR for 
NG 0.82 (95% CI: 0.65-1.04)) compared to those with no CT/NGU/NG in the previous 6 months. 
Among patients with HL-AziR NG, 3 (4%) were treated for CT/NGU and 2 (3%) for NG in the previous 
6 months, compared with 6% and 8% respectively for all GRASP patients. 
 
Conclusions: We found no evidence of an association between previous treatment for CT/NGU or NG 
in GUM services and subsequent presentation with an azithromycin-resistant strain. As many CT 
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diagnoses occur in non-GUM settings, further research is needed to determine whether 
azithromycin-resistant NG is associated with azithromycin exposure in other settings and for other 
conditions. 
 
Key Messages 
1. There was no evidence that previous azithromycin treatment in GUM services was associated 
with subsequent presentation with an azithromycin-resistant strain of Neisseria gonorrhoeae 
(NG). 
2. Azithromycin treatment for STIs in GUM is unlikely to be a major driver for azithromycin 
resistance in NG. 
3. Further research should explore whether azithromycin exposure in other settings and for other 
conditions facilitates azithromycin resistance in NG. 
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INTRODUCTION 
 
Recommended first-line treatment for Neisseria gonorrhoeae (NG) in the UK is with 500 mg 
intramuscularly-injectable ceftriaxone plus 1 g oral azithromycin; this dual therapy approach aims to 
effectively treat patients while preventing the emergence of antimicrobial resistance to 
ceftriaxone[1]. Increasing prevalence of azithromycin resistance in NG, including high-level 
resistance, raises questions about the effectiveness of dual therapy in meeting this aim[2–5]. Given 
evidence that NG is becoming less susceptible to ceftriaxone over time and that there are few new 
antimicrobial agents in the pipeline, the prospect of untreatable gonorrhoea has become a major 
public health concern[5–8]. 
 
Azithromycin has a long half-life[9] and repeat infection with bacterial STIs is common[10], therefore 
it is plausible that treatment of NG and other STIs with azithromycin may facilitate the development 
of resistance by exposing NG to sub-therapeutic levels. Indeed, recent analysis of data from 
attendees at a sexual health clinic in Amsterdam found some evidence of a linear association 
between azithromycin MICs in NG and number of days since previous azithromycin treatment[11]. 
We investigated whether treatment for non-rectal Chlamydia trachomatis (CT), non-gonococcal 
urethritis (NGU), or NG in GUM, as proxies for azithromycin exposure[1,12,13], was associated with 
subsequent NG azithromycin susceptibility using data from the Gonococcal Resistance to 
Antimicrobials Surveillance Programme (GRASP), surveillance of high-level azithromycin-resistant NG 
(HL-AziR; MIC ≥256 mg/L), and the GUMCAD STI Surveillance System in England. 
 
We hypothesised mechanisms by which treatment for STIs with azithromycin could lead to 
decreased azithromycin susceptibility in NG (panel 1). Firstly, treatment for CT may occur while 
concurrent NG infection goes undetected (hypothesis 1a), or a patient could be infected with NG 
shortly after receiving treatment for CT or NGU (hypothesis 1b), both of which could exert selection 
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pressure for azithromycin resistance. Secondly, a patient could be treated for NG but reinfected 
while sub-therapeutic levels of azithromycin are present (hypothesis 2a), or unsuccessfully treated 
for NG with azithromycin monotherapy (hypothesis 2b), again exerting selection pressure for 
resistance, which may then go undetected due to lack of follow up for test of cure.   
{Panel 1 submitted as a separate high resolution image} 
METHODS 
 
Data sources 
Data on azithromycin MIC come from the Gonococcal Resistance to Antimicrobials Programme 
(GRASP) 2013-2015; a detailed description of the GRASP methodology has been published 
elsewhere[2]. Briefly, isolates from individuals with gonorrhoea attending 25 sentinel specialist 
sexual health clinics in England during a three month period each summer 2013-15 were cultured 
and submitted to Public Health England (PHE) for susceptibility testing. An agar dilution method was 
used to determine minimum inhibitory concentrations (MICs) for azithromycin.  All patients 
diagnosed with gonorrhoea at the participating  25 clinics during the data collection period were 
eligible for inclusion in GRASP, however approximately half of episodes do not have susceptibility 
data due to culture not being attempted or successful[14]. Deterministic matching was used to link 
susceptibility data to national electronic STI surveillance data (GUMCAD) on previous attendances at 
that clinic (2012 onwards, as this is the earliest year that patients can be reliably matched to GRASP 
records)[15], using patients’ clinic-specific ID numbers.  
 
The GRASP 2013-15 data included 8 high-level azithromycin resistant (HL-AziR) isolates (MIC ≥256 
mg/L). An additional 54 HL-AziR isolates referred to the National Reference Laboratory at PHE 
between 2013 and September 2016 were matched to GUMCAD (2012-2016) and included in 
analyses of HL-AziR isolates.  
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DST Medium 
The Diagnostic Sensitivity Test (DST) medium used for susceptibility testing for GRASP isolates was 
changed in 2015, whereupon MICs for azithromycin increased[2]. An internal validation study 
compared the MICs determined by the new and old DST agars and found MICs of azithromycin were 
higher by approximately one dilution using the new DST medium. The new DST medium provided 
better pH and physiological conditions for growth of fastidious strains of N. gonorrhoeae which 
subsequently resulted in more reliable azithromycin MIC determination; this was also confirmed by 
local quality assurance data[2]. Azithromycin MIC data for 2013 and 2014 (the years in which the 
problems with growth on the old medium were seen) were therefore adjusted upwards by a factor 
of one dilution to enable more accurate description of trends over time. 
 
Definition of exposures and outcomes 
To identify any differences in susceptibility, not just those resulting in clinically-relevant resistance 
(MIC >0.5 mg/L), the outcomes of interest were modal and mean azithromycin MIC and a binary 
variable indicating elevated azithromycin MIC (>0.25 mg/L) to capture isolates with azithromycin 
intermediate susceptibility (MIC 0.5 mg/L). Exposure variables were attendance with CT, NGU, or NG 
in the previous 6 months (binary variable), time since previous attendance with CT, NGU, or NG 
(categorical variable: <1 month, 1-<6 months, ≥6 months/never), and days since CT, NGU, or NG 
diagnosis (continuous variable). This range of exposures was chosen as, according to our hypotheses, 
we might expect associations with very recent treatment with azithromycin, yet it is also plausible 
that an asymptomatic azithromycin-resistant infection could remain undetected for some time. 
Although NG is likely to spontaneously resolve within weeks or months, the maximum duration of 
infection is unclear[16]. We have assumed that an infection would not remain undetected for more 
than 6 months, and therefore grouped infections diagnosed >6 months previously with never. 
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GUMCAD does not capture information on prescribing, therefore diagnosis with CT, NGU, or NG was 
used as a proxy for azithromycin treatment. In all analyses, previous rectal CT was excluded as 
treatment guidelines recommend treatment with doxycycline rather than azithromycin, and this is 
thought to reflect clinical practice for some time before the change to treatment guidelines in 
2015[12]. Those attending as partners of chlamydia contacts were assumed to have been given 
epidemiological treatment with azithromycin and were therefore included as ‘previous chlamydia’.  
Previous NGU was combined with previous CT, given the small numbers with NGU and similar 
hypothesised mechanisms. As NGU is not always treated with azithromycin[13], sensitivity analyses 
were also performed using previous CT only. Previous CT/NGU were analysed separately to NG due 
to the different hypothesised pathways by which resistance could arise. All hypotheses rely on NG 
being undetected and untreated between the previous CT/NGU/NG attendance and the GRASP NG 
episode, therefore we used GUMCAD records to exclude any previous attendances which had been 
followed by a negative NG test more than 20 days after the most recent CT/NGU/NG episode. 
Previous attendances followed by a test of cure within 20 days were not excluded as hypotheses 1b) 
and 2a) propose (re-)infection shortly after treatment as a mechanism for the development of 
resistance, which could potentially occur even where a test of cure had been carried out. The half-
life of azithromycin is 1-4 days in tissues, therefore azithromycin would be expected to have cleared 
from tissues in under 20 days following treatment[9]. 
  
Descriptive and statistical analyses 
Descriptive analyses of MIC distribution in NG (histograms) by history of previous attendance with 
CT/NGU (hypotheses 1a and 1b) and NG (hypotheses 2a and 2b) were performed for all GRASP 
isolates. Due to the dispersed nature of MIC data, negative binomial regression was used to assess 
differences in azithromycin MIC distribution by history of CT/NG, with resulting Incidence Rate 
Ratios (IRRs) indicating the relative difference in predicted (mean) MIC compared with the reference 
category (previous episode >6 months ago or no previous episodes). Multivariable analyses were 
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adjusted for year, age, and gender/sexual orientation (groupings: MSM, heterosexual men, all 
women). Crude and multivariable logistic regression were used to determine associations between 
previous attendances and elevated azithromycin MIC (>0.25 mg/L). Linear regression of azithromycin 
MIC (transformed on the natural logarithm scale due to over-dispersion and skewed distribution) by 
days since previous CT/NGU or NG was performed to assess evidence of a time-dependent 
association with previous azithromycin treatment (previous month). Clustering of azithromycin 
resistance within clinics was accounted for in all regression analyses using generalised estimating 
equations under the assumption of an exchangeable correlation matrix[17]. Data for the 62 HL-AziR 
isolates were analysed descriptively due to the lack of a comparison group. Analyses were carried 
out using Stata version 13 (Stata Statistical Software: Release 13. College Station, Texas, USA: 
StataCorp, 2013). 
 
Ethics and governance 
In its role providing infectious disease surveillance Public Health England has permission to handle 
data obtained by GRASP, GUMCAD, and the reference laboratory under Regulation 3 of the Health 
Service (Control of Patient Information) Regulations 2002.  
 
RESULTS 
  
Among the 4606 GRASP patients, 6% (n=263) had attended that clinic in the previous 6 months with 
CT, 1% (n=49) with NGU, and 8% (n=369) with NG (appendix table 1). Modal azithromycin MIC was 
0.25 mg/L (one dilution below the resistance breakpoint). This did not vary by treatment for CT/NGU 
or NG in the previous 1 month/6 months (appendix figure 1).There was no evidence of a difference 
in predicted azithromycin MICs by experience of previous CT/NGU or NG in the previous 6 months 
(p-values 0.97 and 0.71 respectively, data not shown), and no differences by recency of previous 
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CT/NGU or NG episode (p-values 0.98 and 0.85 respectively) in the negative binomial regression 
model adjusted for year, age, and gender/sexual orientation (table 1). 
 
According to the logistic regression model, there was no evidence of an association between 
elevated azithromycin MIC (>0.25 mg/L) and treatment for CT/NGU (Adjusted Odds Ratio 0.97 [95% 
Confidence Interval 0.76-1.25]) or NG (AOR 0.82 [95% CI: 0.65-1.04]) in the previous 6 months (Table 
2). A sensitivity analysis replicating this logistic regression but using the outcome of azithromycin 
resistance (MIC >0.5 mg/L) also found no evidence of an association with CT/NG (p=0.49) or NG 
(p=0.81) in the previous 6 months. Furthermore, linear regression of the natural logarithm (ln) of 
azithromycin MIC on days since previous CT/NGU or NG found no evidence that azithromycin MIC 
was higher among those who had been most recently treated (figure 1). Sensitivity analyses 
examining previous CT exposure only found similar results for all regression analyses as reported 
here for previous CT/NGU combined (data not shown).  
 
Among the 62 high-level azithromycin-resistant (HL-AziR) NG patients identified either in GRASP or 
referred to the national reference laboratory at PHE, 3 (4%) were treated for CT/NGU and 2 (3%) 
were treated for NG in the previous 6 months (table 3). There was therefore no indication that this 
was more common in HL-AziR isolates than among all GRASP isolates (corresponding figures for all 
GRASP isolates: 6% for CT/NGU, 8% for NG). 
 
 
DISCUSSION 
 
We found no evidence of an association between azithromycin susceptibility in NG and previous 
treatment for chlamydia, non-gonococcal urethritis, or gonorrhoea in these national GUM clinic 
surveillance data. These findings suggest that the use of azithromycin to treat STIs in British sexual 
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health clinics is not a major driver for azithromycin resistance in NG. Other potential drivers, such as 
the use of azithromycin to treat infections in other settings and importation of resistant strains of 
NG, may therefore warrant investigation. It should also be borne in mind that evidence from whole 
genome sequencing of the high-level azithromycin resistant NG outbreak indicated that most of 
these cases were clonal, suggesting that in most cases resistance was sexually acquired rather than 
de novo development[3,18]. Thus, in a sentinel surveillance programme such as GRASP it may be 
difficult to detect the case where the mutation leading to azithromycin resistance first arose.  
 
A strength of this analysis was the ability to combine azithromycin MIC data with complete episode-
level information on previous clinic attendances. However, as patient data cannot be linked across 
different clinics or with other health services, this is likely lead to some underestimation of previous 
azithromycin exposure for the treatment of STIs. As information about prescribing is not captured in 
GUMCAD, we made assumptions about treatment of STIs with azithromycin which would not always 
be correct, however we would expect these to be accurate in the majority of cases. For example 
audit data from 2015 found 83% of chlamydia cases in specialist sexual health clinics were treated 
with azithromycin (English National Chlamydia Screening Programme (NCSP) audit team, personal 
communication, 24th August 2017). It is also possible that our data may underestimate recent 
treatment of NGU prior to gonorrhoea episodes, in circumstances where a patient is initially treated 
for NGU which is subsequently confirmed as gonorrhoea by laboratory tests. In these cases, clinics 
may not retain the original record of NGU in the surveillance dataset thus in some cases leading to 
under-reporting. Finally, the relatively small number of patients treated for CT or NGU in the 
previous month precluded analysing this exposure group separately in the logistic regression 
analysis, although we were able to present analyses of this group for the linear and negative 
binomial regressions which take into account the full MIC distribution.  Despite these limitations, the 
lack of any indication of an association found in these data suggests the relative contribution of 
previous azithromycin treatment for STIs on azithromycin resistance in NG is likely to be small. 
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Other authors have raised concerns about the impact of widespread use of azithromycin on 
azithromycin resistance in STIs including NG[5,19,20], and some published case reports have 
documented development of de novo azithromycin resistance within individual patients treated with 
azithromycin monotherapy[21,22]. Our findings contrast partly with the only comparable 
epidemiological study on this topic, which found evidence of a linear association between days since 
azithromycin treatment and azithromycin MIC, among a sub-analysis of 14 patients treated with 
azithromycin in the previous 30 days in an STI clinic in Amsterdam[11]. Azithromycin MICs in that 
study were tested using the E-test method, which generates more MIC values than agar dilution (as 
used in our study), thus it is possible that our data on azithromycin MIC were not fine-grained 
enough to identify a linear trend. However, even with our less detailed MIC data, we would expect 
to see some indication of a trend if an association it existed in this setting. Analysis of other time 
frames in the Amsterdam study did not yield any associations, in line with our findings[11]. 
Previously, GRASP and the European Gonococcal Antimicrobial Surveillance Programme have found 
associations between azithromycin resistance and previous NG infection[23,24], however neither 
study was designed to test this specific hypothesis and lacked detailed information on exposure 
intervals. An ecological study in the USA found no association between regional outpatient 
prescribing of specific antibiotics, including azithromycin, and NG susceptibility[25], leading the 
authors to propose that the importation of resistant strains may play a greater role than domestic 
prescribing practice, which may also be relevant in the UK context.  
 
We found no evidence from national surveillance data that treatment of STIs with azithromycin in 
GUM is driving azithromycin resistance in NG. However, as we could not explore prior exposure in 
general practice or other settings our findings may have limited generalizability to other settings, 
and only go part way towards answering questions about the impact of widespread azithromycin 
use, including by the NCSP, on the emergence of resistance in NG. In these settings patients are less 
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likely to be tested for gonorrhoea, making our hypothesis of undiagnosed gonorrhoea being exposed 
to azithromycin (without appropriate follow-up/test of cure) more likely. However, a 2013 survey of 
NCSP commissioners found over half of commissioners were using dual CT/NG testing[26], and this 
figure is likely to have increased since then. Further data on the extent to which testing and 
management of NG diagnosed outside specialist sexual health clinics is carried out in line with 
national guidelines[1,27] would provide better understanding of the generalizability of these results 
to other settings. Although overall data on GP azithromycin prescribing exists via the Open 
Prescribing tool[28], a more detailed breakdown by age and other risk factors for NG would shed 
light on the extent to which the group at risk of NG are exposed to azithromycin more generally 
outside GUM. Despite the limitations of the available data, the findings presented here call into 
question assumptions that azithromycin use for the treatment of STIs is a major factor in the 
development of resistance, although further research into the mechanisms of emergence of 
azithromycin resistance in NG including exposure to azithromycin in other settings and for other 
conditions, is needed.  
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Table and figures  
 
Table 1: Association between previous treatment for chlamydia/NGU or gonorrhoea and subsequent azithromycin MIC in Neisseria gonorrhoeae 
(negative binomial regression) (GRASP 2013-15, England) 
    N 
Modal MIC 
(mg/L) 
crude 
IRR 95% CI p-value  
adjusted 
IRR 95% CI p-value  
Previous attendance 
for NGU or 
chlamydiaa,b 
never/>6 months ago 4299 0.25 1.00 - 0.98 1.00 - 0.98 
1-<6 months 269 0.25 1.01 (0.88-1.16)   1.00 (0.87-1.15)   
<1 month 38 0.25 1.01 (0.71-1.43)   1.03 (0.72-1.49)   
Previous attendance 
for gonorrhoeaa 
never/>6 months ago 4237 0.25 1.00 - 0.81 1.00 - 0.85 
1-<6 months 322 0.25 1.00 (0.88-1.14)   0.99 (0.87-1.12)   
<1 month 47 0.06 0.90 (0.66-1.24)   0.91 (0.65-1.28)   
a Only previous episodes at that clinic are known; excludes those with a subsequent negative gonorrhoea test 
b  Excludes rectal chlamydia. Includes epidemiological treatment for chlamydia. 
NGU=Non-gonococcal urethritis 
IRR=incidence rate ratio for increasing MIC dilutions calculated using negative binomial regression. Adjusted IRR adjusted for year, age, gender/sexual orientation. Clinic-level 
clustering accounted for using Generalised Estimating Equations. 
Azithromycin data for 2013-14 adjusted to account for problem with the DST medium (see methods for further details) 
 
 
Table 2: Association between treatment for CT/NGU or NG in the previous 6 months and elevated azithromycin MIC (>0.25 mg/L) (GRASP 2013-15, 
England) 
    N % 
crude 
OR 95% CI p-value  
adjusted 
OR 95% CI p-value  
Previous attendance 
for NGU or 
chlamydiaa,b 
never/>6 months ago 4299 32.5 1.00 - 0.91 1.00 - 0.81 
<6 months 307 33.9 1.01 (0.79-1.30) 
 
0.97 (0.76-1.25) 
 
Previous attendance 
for gonorrhoeaa 
never/>6 months ago 4237 32.7 1.00 - 0.26 1.00 - 0.10 
<6 months 369 31.2 0.87 (0.69-1.11) 
 
0.82 (0.65-1.04) 
 
a Only previous episodes at that clinic are known; excludes those with a subsequent negative gonorrhoea test 
b  Excludes rectal chlamydia. Includes epidemiological treatment for chlamydia. 
OR=Odds Ratio calculated using logistic regression. Adjusted OR adjusted for year, age, gender/sexual orientation. Clinic-level clustering accounted for using Generalised 
Estimating Equations. 
Azithromycin data for 2013-14 adjusted to account for problem with the DST medium (see methods for further details) 
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Figure 1: Linear regression of ln(azithromycin MIC) (GRASP 2013-15, England) by days since 
previous: 
a) chlamydia or non-gonococcal urethritis a,b 
b) gonorrhoea a 
 
{Figure 1 submitted separately as a high resolution image} 
 
Figure 1 footnotes: 
a Excludes rectal CT. Includes epidemiological treatment for chlamydia. 
b Only previous episodes at that clinic are known; excludes cases with subsequent negative NG test >20 days 
after previous CT episode 
Linear regression p-values:  
a) CT/NGU: i) <1 month p=0.71, ii) 1-3 months p= 0.72, iii) 3-6 months p=0.04 
b) NG: i) <1 month p=0.77, ii) 1-3 months p=0.09, iii) 3-6 months p=0.74 
 
 
Table 3: descriptive analysis of previous attendances for CT/NGU or NG among n=62 high-level 
azithromycin-resistant Neisseria gonorrhoeae isolates in England (n=8 from GRASP 2013-2015, 
n=54 cases referred to the National Reference Laboratory at Public Health England 2013-16) 
    n % 
Previous 
attendance for NGU 
or chlamydiaa,b 
never/ >6 months ago 59 88% 
1 - <6 months 3 4% 
<1 month 0 0% 
Previous 
attendance for 
gonorrhoeaa 
never/ >6 months ago 60 90% 
1 - <6 months 2 3% 
<1 month 0 0% 
 
 a Only previous episodes at that clinic are known; excludes those with a subsequent negative gonorrhoea test 
b  Excludes rectal chlamydia. Includes epidemiological treatment for chlamydia. 
n=54 Cases HL-AziR cases identified via the Bacterial Reference Laboratory, n=8 identified via GRASP 
